Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
JAMA Oncol. 2018 Mar 08;:
Leuk Res. 2018 Feb 20;68:22-28
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Haematologica. 2016 12;101(12):e482-e484
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Blood Adv. 2017 Sep 12;1(20):1729-1738
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Lancet Haematol. 2017 Dec 20;:
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.
Oncotarget. 2017 Oct 24;8(51):89256-89268
Impact of comorbidities constituting the HCT-CI score on the outcome of patients undergoing allogeneic HCT for AML.
Eur J Haematol. 2017 Nov 23;:
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM.
Curr Hematol Malig Rep. 2017 Nov 06;:
Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN.
Curr Hematol Malig Rep. 2017 Oct 24;:
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
J Hematol Oncol. 2017 Sep 29;10(1):156